| Bioactivity | Encainide (MJ9067) is an antiarrhythmic drug with class IC activity. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research[1]. | ||||||||||||
| In Vivo | Encainide (0.3, 0.9, 2.7 mg/kg; infusion of single doses) prolongs His-Purkinje conduction time (HV interval) and intra-ventricular conduction time (QRS duration) but has no effect on sinus nodal recovery time or AV nodal conduction, or on refractoriness of atrium, AV node, or ventricular myocardium or on QT interval[1]. | ||||||||||||
| Name | Encainide | ||||||||||||
| CAS | 66778-36-7 | ||||||||||||
| Formula | C22H28N2O2 | ||||||||||||
| Molar Mass | 352.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. R N Brogden, et al. Encainide. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1987 Nov;34(5):519-38. |